Thirty-three patients (symptPAT, mean age: 43.3 ± 12.8, 23 females/10 males, IgG, IgM, IgA data not available) were examined by a neurologist after contraction of SARS-CoV-2 and they had experienced persistent neurological symptoms for at least two months following a history of COVID-19 infection: fatigue (76%), concentration and memory problems (67%), headaches (73%), muscle and joint pain (64%), cough (48%), loss of taste and smell (52%), hospitalization (15%), insomnia (48%), and psychological problems (21%). The gene discussed is CD79A; the disease is insomnia measurement.